Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.

Wick W, Krendyukov A, Junge K, Höger T, Fricke H.

J Neurooncol. 2019 Dec;145(3):531-540. doi: 10.1007/s11060-019-03320-x. Epub 2019 Nov 2.

PMID:
31679112
2.

HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.

Richards DM, Marschall V, Billian-Frey K, Heinonen K, Merz C, Redondo Müller M, Sefrin JP, Schröder M, Sykora J, Fricke H, Hill O, Gieffers C, Thiemann M.

J Immunother Cancer. 2019 Jul 19;7(1):191. doi: 10.1186/s40425-019-0671-4.

3.

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.

Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T.

Pharmaceutics. 2019 Apr 1;11(4). pii: E152. doi: 10.3390/pharmaceutics11040152.

4.

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity.

Thiemann M, Richards DM, Heinonen K, Kluge M, Marschall V, Merz C, Redondo Müller M, Schnyder T, Sefrin JP, Sykora J, Fricke H, Gieffers C, Hill O.

Front Oncol. 2018 Sep 19;8:387. doi: 10.3389/fonc.2018.00387. eCollection 2018.

5.

The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.

Merz C, Sykora J, Marschall V, Richards DM, Heinonen K, Redondo Müller M, Thiemann M, Schnyder T, Fricke H, Hill O, Gieffers C.

J Immunother. 2018 Nov/Dec;41(9):385-398. doi: 10.1097/CJI.0000000000000246.

PMID:
30273198
6.

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.

Legler K, Hauser C, Egberts JH, Willms A, Heneweer C, Boretius S, Röcken C, Glüer CC, Becker T, Kluge M, Hill O, Gieffers C, Fricke H, Kalthoff H, Lemke J, Trauzold A.

Cell Death Dis. 2018 May 1;9(5):445. doi: 10.1038/s41419-018-0478-0.

7.

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.

Boch T, Luft T, Metzgeroth G, Mossner M, Jann JC, Nowak D, Meir F, Schumann C, Klemmer J, Brendel S, Fricke H, Kunz C, Weiß C, Hofmann WK, Nolte F.

Leuk Res. 2018 May;68:62-69. doi: 10.1016/j.leukres.2018.03.007. Epub 2018 Mar 10.

PMID:
29549809
8.

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.

Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D.

Mol Cancer Res. 2018 May;16(5):767-776. doi: 10.1158/1541-7786.MCR-17-0563. Epub 2018 Feb 16.

9.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Raimbault A, Pierre-Eugene C, Rouquette A, Deudon C, Willems L, Chapuis N, Mathis S, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M; Groupe Francophone des Myélodysplasies.

Oncotarget. 2016 Mar 22;7(12):14898-911. doi: 10.18632/oncotarget.7469.

10.

Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.

Merz C, Strecker A, Sykora J, Hill O, Fricke H, Angel P, Gieffers C, Peterziel H.

Anticancer Drugs. 2015 Aug;26(7):716-27. doi: 10.1097/CAD.0000000000000237.

11.

A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.

Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE.

Clin Cancer Res. 2014 Dec 15;20(24):6304-13. doi: 10.1158/1078-0432.CCR-14-0951-T. Epub 2014 Oct 22.

12.

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.

Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R, Fischer C, Branschädel M, Abhari BA, Hohenberger P, Fulda S, Fricke H, Hill O.

Mol Cancer Ther. 2013 Dec;12(12):2735-47. doi: 10.1158/1535-7163.MCT-13-0323. Epub 2013 Oct 7.

13.

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions.

Hartmann N, Messmann JJ, Leithäuser F, Weiswange M, Kluge M, Fricke H, Debatin KM, Strauss G.

Blood. 2013 Jan 17;121(3):556-65. doi: 10.1182/blood-2012-04-423392. Epub 2012 Nov 30.

PMID:
23203823
14.

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.

Tuettenberg J, Seiz M, Debatin KM, Hollburg W, von Staden M, Thiemann M, Hareng B, Fricke H, Kunz C.

Int Immunopharmacol. 2012 May;13(1):93-100. doi: 10.1016/j.intimp.2012.03.004. Epub 2012 Mar 21.

PMID:
22446296
15.

Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer.

Formentini A, Braun P, Fricke H, Link KH, Henne-Bruns D, Kornmann M.

Int J Colorectal Dis. 2012 Oct;27(10):1369-76. Epub 2012 Mar 24.

PMID:
22441356
16.

Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener's granulomatosis and Churg-Strauss syndrome.

Wieczorek S, Holle JU, Bremer JP, Wibisono D, Moosig F, Fricke H, Assmann G, Harper L, Arning L, Gross WL, Epplen JT.

Rheumatology (Oxford). 2010 May;49(5):907-14. doi: 10.1093/rheumatology/kep420. Epub 2010 Feb 25.

PMID:
20185531
17.

A functionally relevant IRF5 haplotype is associated with reduced risk to Wegener's granulomatosis.

Wieczorek S, Holle JU, Müller S, Fricke H, Gross WL, Epplen JT.

J Mol Med (Berl). 2010 Apr;88(4):413-21. doi: 10.1007/s00109-009-0580-y. Epub 2010 Jan 5.

PMID:
20049410
18.

Quantitative myocardial perfusion PET combined with coronary anatomy derived from CT angiography: validation of a new fusion and visualisation software.

Fricke H, Elsner A, Weise R, Bolte M, van den Hoff J, Burchert W, Domik G, Fricke E.

Z Med Phys. 2009;19(3):182-8.

PMID:
19761095
19.

Myocardial perfusion after one year of spinal cord stimulation in patients with refractory angina.

Fricke E, Eckert S, Dongas A, Fricke H, Preuss R, Lindner O, Horstkotte D, Burchert W.

Nuklearmedizin. 2009;48(3):104-9. doi: 10.3413/nukmed-0210. Epub 2009 Jan 14.

PMID:
19295969
20.

Myocardial sympathetic innervation in patients with symptomatic coronary artery disease: follow-up after 1 year with neurostimulation.

Fricke E, Eckert S, Dongas A, Fricke H, Preuss R, Lindner O, Horstkotte D, Burchert W.

J Nucl Med. 2008 Sep;49(9):1458-64. doi: 10.2967/jnumed.108.052340. Epub 2008 Aug 14.

Supplemental Content

Loading ...
Support Center